Ozuna, Lorena Miss published the artcileDupilumab-associated arthralgia in patients with aspirin-exacerbated respiratory disease, Synthetic Route of 169590-42-5, the publication is Annals of Allergy, Asthma, & Immunology (2022), 128(4), 469-472, database is CAplus and MEDLINE.
Dupilumab is generally safe and well-tolerated; however, in a phase 3 clin. trial of dupilumab for CRSwNP, arthralgias were reported 4.7% and 7.4% of patients in the treatment arms compared with 1.3% of patients in the placebo arm. In this study, we evaluate the clin. characteristics and outcomes of 8 patients with AERD who developed arthralgias after initiating dupilumab. Of 160 patients with AERD treated with dupilumab at our center, we identified 8 patients (5.0%) who reported possible dupilumab-associated arthralgias at their allergy and immunol. follow-up visit. Several patients sought treatment for the arthralgias and were prescribed celecoxib or oral and intra-articular corticosteroids. Of the 8 patients, 5 had spontaneous resolution of their pain after an average of 6.9 mo, whereas arthralgias in 3 patients remain unresolved. Furthermore, our clin. outcomes were limited to the evaluations performed by the clinician caring for the patient and not all patients had a complete inflammatory and rheumatol. workup for their symptoms. Joint symptoms are very common in adults and may have been unrelated to dupilumab. Lastly, the mechanism of dupilumab-associated arthralgias is not clear, but a possible mechanism is a shift toward a type 1 or type 3 immune profile which may be indicative of a type 1 or type 3 “escape” with inhibition of IL-4Ra. Further studies to under-stand the mechanism of dupilumab-associated arthralgias are warranted. Clinicians caring for patients with AERD encountering this adverse effect should use shared decision-making to determine whether patients can continue dupilumab with close follow-up.
Annals of Allergy, Asthma, & Immunology published new progress about 169590-42-5. 169590-42-5 belongs to amides-buliding-blocks, auxiliary class Sulfamide,Immunology/Inflammation,COX, name is 4-(5-(p-Tolyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide, and the molecular formula is C17H14F3N3O2S, Synthetic Route of 169590-42-5.
Referemce:
https://en.wikipedia.org/wiki/Amide,
Amide – an overview | ScienceDirect Topics